New blood test for diagnosing liposarcomas

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project aims to identify a new non-invasive blood biomarker for diagnosing liposarcomas by measuring circulating serine levels. Currently, the gold standard for diagnosis involves detecting Mdm2 amplification through a tumor biopsy, which can be invasive and limited. The study will involve blood sampling from patients with localized and relapsed liposarcomas, as well as healthy subjects matched by age and sex. The goal is to improve diagnostic accuracy and reduce the need for invasive procedures.

Why it matters

Who can join: the full rules

Inclusion Criteria for LPS patients cohort:

Men/women older than 18 years old,

Surgery for :

* Localized WD-LPS and DD-LPS, and/or
* WD-LPS or DD-LPS local relapse, and/or
* WD-LPS or DD-LPS distant relapse and/or
* Deep adipocytic tumor greater than 5 cms, suggestive of atypical lipomatous tumor Patient accepting blood sample, Patient who signed informed consent

Inclusion Criteria for healthy subjects cohort:

Men/women older than 18 years old, Accepting blood sample, Who signed informed consent Matching on sex and age on LPS patient cohort

Exclusion Criteria:

Presence of NeoAdjuvant Treatment for the present cancer, Unaffiliated patient to French Social Protection System, Patient whose follow up is impossible for psychologic, social, geographic, familial reasons Psychiatric illness that would prevent the patient from giving informed consent or being compliant with the study procedures Patient who have another cancer within the 5 years of the inclusion except in situ breast carcinoma, in situ, basocellular carcinoma.

Pregnancy and/or feeding

Where it's running

• Institut du Cancer de Montpellier - Val d'Aurelle
  Montpellier, France Recruiting

Study contacts

• Study coordinator: Jean-Pierre BLEUSE, MD
• Email: DRCI-icm105@icm.unicancer.fr
• Phone: 0467613102

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Personalised neoadjuvant therapy planning for adults with high‑risk soft tissue sarcoma

  This project tests whether analyzing tumor tissue and clinical data can help guide neoadjuvant chemotherapy decisions for adults with high‑risk soft tissue sarcomas.

  Recruiting Royal Marsden NHS Foundation Trust · London · NCT07432932

• Dose‑escalated, short‑course proton radiation for inoperable soft tissue sarcoma

  This will try higher-dose, shorter-course proton radiation to see if it controls tumors better in adults with inoperable soft tissue sarcoma.

  Recruiting Phase 2 Oslo University Hospital · Bergen and 1 other locations · NCT07173972

• Three-week preoperative proton versus X-ray radiotherapy for localized soft tissue sarcoma

  This trial tests whether selecting proton rather than standard X‑ray radiotherapy before surgery for adults with localized soft tissue sarcoma can lower long-term radiation side effects without increasing surgical complications.

  Recruiting Phase 2 Oslo University Hospital · Bergen and 3 other locations · NCT07169344

• GPC3-targeted CAR T cells armored with IL-15 and IL-21 for pediatric non‑CNS solid tumors

  This treatment will try personalized CAR T cells that target GPC3 and are engineered to make IL‑15 and IL‑21 in children and young adults with relapsed or refractory non‑CNS solid tumors that express GPC3.

  Recruiting Phase 1 Seattle Children's Hospital · Seattle, Washington · NCT07148050

• Testing mirdametinib with palbociclib for treating liposarcoma

  This study is testing a new combination of two medications, mirdametinib and palbociclib, to see if they can help people with advanced liposarcoma feel better and improve their treatment options.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT06843967

• Using silmitasertib with chemotherapy for relapsed solid tumors

  This study is testing a new drug called silmitasertib combined with chemotherapy to see if it helps people with relapsed solid tumors feel better and manage their cancer.

  Recruiting at 24 sites Phase 1/2 Milton S. Hershey Medical Center · Birmingham, Alabama and 23 other locations · NCT06541262

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.